Merck KGaA (FRA:MRK) Given a €104.00 Price Target by Deutsche Bank Analysts
Deutsche Bank set a €104.00 ($120.93) price target on Merck KGaA (FRA:MRK) in a report issued on Tuesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
MRK has been the subject of a number of other reports. Morgan Stanley set a €96.00 ($111.63) price target on Merck KGaA and gave the stock a neutral rating in a report on Tuesday, September 10th. Credit Suisse Group set a €110.00 ($127.91) price target on Merck KGaA and gave the stock a buy rating in a report on Friday, September 6th. Sanford C. Bernstein set a €114.00 ($132.56) price target on Merck KGaA and gave the stock a neutral rating in a report on Wednesday, October 9th. Bank of America set a €110.00 ($127.91) price target on Merck KGaA and gave the stock a neutral rating in a report on Friday, September 13th. Finally, Barclays set a €82.00 ($95.35) price target on Merck KGaA and gave the stock a sell rating in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of €101.78 ($118.35).
Shares of MRK stock traded down €3.60 ($4.19) during trading hours on Tuesday, reaching €106.15 ($123.43). 1,028,425 shares of the company’s stock were exchanged. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72). The business has a fifty day moving average price of €105.33 and a 200-day moving average price of €96.85.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: What does an inverted yield curve signify?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.